-
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Antimicrobial agents and chemotherapy 20171201
-
Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
Antimicrobial agents and chemotherapy 20170801
-
Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.
Bioorganic & medicinal chemistry 20160901
-
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Antimicrobial agents and chemotherapy 20150101
-
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
Journal of medicinal chemistry 20140227
-
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20140201
-
Characterization of binding of raltegravir to plasma proteins.
Antimicrobial agents and chemotherapy 20131001
-
Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.
Journal of molecular recognition : JMR 20130901
-
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet (London, England) 20130824
-
Antiretroviral therapy: dolutegravir sets SAIL(ING).
Lancet (London, England) 20130824
-
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
The Lancet. Infectious diseases 20130701
-
Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.
Antimicrobial agents and chemotherapy 20130301
-
Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.
Journal of inorganic biochemistry 20130101
-
Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Journal of medical virology 20121201
-
Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.
AIDS (London, England) 20121113
-
A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.
Journal of pharmaceutical and biomedical analysis 20121101
-
The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.
Journal of acquired immune deficiency syndromes (1999) 20121101
-
A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
Journal of acquired immune deficiency syndromes (1999) 20121101
-
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
Atherosclerosis 20121101
-
A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
AIDS research and human retroviruses 20121001
-
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20121001
-
Risk factors for raltegravir resistance development in clinical practice.
The Journal of antimicrobial chemotherapy 20121001
-
Raltegravir-induced DRESS syndrome.
Scandinavian journal of infectious diseases 20121001
-
The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
AIDS (London, England) 20120924
-
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
AIDS (London, England) 20120910
-
Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.
AIDS research and human retroviruses 20120901
-
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
Journal of acquired immune deficiency syndromes (1999) 20120901
-
The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
Current opinion in HIV and AIDS 20120901
-
Pharmacology of HIV integrase inhibitors.
Current opinion in HIV and AIDS 20120901
-
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.
AIDS patient care and STDs 20120901
-
HIV integrase inhibitors in ART-experienced patients.
Current opinion in HIV and AIDS 20120901
-
Tolerability of HIV integrase inhibitors.
Current opinion in HIV and AIDS 20120901
-
Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012.
Molecules (Basel, Switzerland) 20120827
-
Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.
AIDS (London, England) 20120824
-
Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients.
AIDS research and human retroviruses 20120801
-
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
British journal of clinical pharmacology 20120801
-
Pharmacokinetic and safety of raltegravir in pregnancy.
European journal of clinical pharmacology 20120801
-
Design, synthesis and antiviral activity of novel pyridazines.
European journal of medicinal chemistry 20120801
-
Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study.
Molecular bioSystems 20120801
-
Testing superiority at interim analyses in a non-inferiority trial.
Statistics in medicine 20120710
-
Low frequency of skin reactions in a cohort of patients on raltegravir.
The Journal of antimicrobial chemotherapy 20120701
-
In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
Antiviral research 20120701
-
Update on raltegravir and the development of new integrase strand transfer inhibitors.
Southern medical journal 20120701
-
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
International journal of STD & AIDS 20120701
-
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Journal of acquired immune deficiency syndromes (1999) 20120601
-
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
PLoS pathogens 20120601
-
[Undetectable viral load after the addition of raltegravir in a 36 week pregnant adolescent with high-level HIV viraemia].
Anales de pediatria (Barcelona, Spain : 2003) 20120501
-
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Gastroenterology 20120501
-
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Journal of acquired immune deficiency syndromes (1999) 20120415
-
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].
Enfermedades infecciosas y microbiologia clinica 20120401
-
Discovery of drugs that possess activity against feline leukemia virus.
The Journal of general virology 20120401
-
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
Journal of acquired immune deficiency syndromes (1999) 20120401
-
Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors.
European journal of medicinal chemistry 20120401
-
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Therapeutic drug monitoring 20120401
-
Role of raltegravir in HIV-1 management.
The Annals of pharmacotherapy 20120401
-
Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.
AIDS (London, England) 20120313
-
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
AIDS (London, England) 20120313
-
Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.
Journal of clinical pharmacology 20120301
-
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 20120301
-
Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
The Pediatric infectious disease journal 20120301
-
Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.
Journal of chemical information and modeling 20120227
-
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.
AIDS (London, England) 20120220
-
[Raltegravir in HIV-infected patients with high vascular risk].
Medicina clinica 20120218
-
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
The Journal of infectious diseases 20120215
-
Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
AIDS research and human retroviruses 20120201
-
Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
HIV medicine 20120201
-
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Pharmacological research 20120201
-
Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
Chemical biology & drug design 20120201
-
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.
The Journal of antimicrobial chemotherapy 20120201
-
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral research 20120201
-
Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Pharmacotherapy 20120201
-
Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
AIDS (London, England) 20120114
-
Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
Haemophilia : the official journal of the World Federation of Hemophilia 20120101
-
Antiviral effect of raltegravir on HTLV-1 carriers.
The Journal of antimicrobial chemotherapy 20120101
-
Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101
-
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
The Lancet. Infectious diseases 20120101
-
Elvitegravir: a once daily alternative to raltegravir.
The Lancet. Infectious diseases 20120101
-
Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Current medicinal chemistry 20120101
-
Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101
-
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Antiviral therapy 20120101
-
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Antiviral therapy 20120101
-
HIV-associated gastric natural killer/T-cell lymphoma.
International journal of STD & AIDS 20120101
-
Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.
Pharmacotherapy 20120101
-
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
PloS one 20120101
-
Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Intervirology 20120101
-
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV clinical trials 20120101
-
Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.
PloS one 20120101
-
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
PloS one 20120101
-
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV clinical trials 20120101
-
The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.
Antiviral therapy 20120101
-
Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
PloS one 20120101
-
Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 'deep' sequencing.
PloS one 20120101
-
Elevated liver enzymes resulting from an interaction between Raltegravir and Panax ginseng: a case report and brief review.
Drug metabolism and drug interactions 20120101
-
Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors.
Journal of medicinal chemistry 20111222
-
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 20111215
-
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
The Journal of infectious diseases 20111215
-
Autoimmune disease: A role for new anti-viral therapies?
Autoimmunity reviews 20111201
-
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
The Lancet. Infectious diseases 20111201
-
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
The Journal of antimicrobial chemotherapy 20111201
-
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
The Journal of infectious diseases 20111201
-
A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.
The Journal of pharmacy and pharmacology 20111201
-
Cost-effectiveness of raltegravir in HIV/AIDS.
Expert review of pharmacoeconomics & outcomes research 20111201
-
Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
AIDS (London, England) 20111128
-
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
AIDS (London, England) 20111128
-
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
The Journal of infectious diseases 20111115
-
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
AIDS (London, England) 20111113
-
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.
AIDS (London, England) 20111113
-
The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.
Medical microbiology and immunology 20111101
-
MK-0536 inhibits HIV-1 integrases resistant to raltegravir.
Antimicrobial agents and chemotherapy 20111101
-
Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111101
-
Switching between raltegravir resistance pathways analyzed by deep sequencing.
AIDS (London, England) 20111023
-
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
Journal of clinical pharmacology 20111001
-
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001
-
[Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].
Deutsche medizinische Wochenschrift (1946) 20111001
-
Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
PLoS pathogens 20111001
-
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Medicina clinica 20110910
-
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
The Journal of antimicrobial chemotherapy 20110901
-
IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.
Blood 20110901
-
Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir.
Veterinary microbiology 20110826
-
DRESS syndrome associated with raltegravir.
Dermatology online journal 20110815
-
Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors.
Molecules (Basel, Switzerland) 20110811
-
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
The Journal of antimicrobial chemotherapy 20110801
-
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Antiviral research 20110801
-
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
AIDS (London, England) 20110731
-
HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex.
Journal of molecular biology 20110729
-
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies.
AIDS (London, England) 20110717
-
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
AIDS research and human retroviruses 20110701
-
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
The Journal of antimicrobial chemotherapy 20110701
-
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
The Journal of antimicrobial chemotherapy 20110701
-
Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.
AIDS (London, England) 20110619
-
Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Journal of clinical pharmacology 20110601
-
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20110601
-
Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
The Journal of antimicrobial chemotherapy 20110601
-
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.
The Journal of antimicrobial chemotherapy 20110601
-
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Antiviral research 20110601
-
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
AIDS (London, England) 20110601
-
Raltegravir in pregnancy: a case series presentation.
International journal of STD & AIDS 20110601
-
[Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
MMW Fortschritte der Medizin 20110505
-
Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.
Joint, bone, spine : revue du rhumatisme 20110501
-
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.
Journal of acquired immune deficiency syndromes (1999) 20110501
-
HIV-1 integrase inhibitor resistance and its clinical implications.
The Journal of infectious diseases 20110501
-
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Bioanalysis 20110501
-
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
AIDS (London, England) 20110424
-
Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110401
-
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Journal of acquired immune deficiency syndromes (1999) 20110401
-
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
The Journal of antimicrobial chemotherapy 20110401
-
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
The Journal of antimicrobial chemotherapy 20110401
-
Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.
British journal of clinical pharmacology 20110401
-
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
The Journal of infectious diseases 20110401
-
Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes.
Current HIV research 20110401
-
Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
AIDS (London, England) 20110313
-
Severe insomnia related to high concentrations of raltegravir.
AIDS (London, England) 20110313
-
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
Journal of clinical pharmacology 20110301
-
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.
Pharmacological research 20110301
-
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
The Annals of pharmacotherapy 20110301
-
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Annals of the New York Academy of Sciences 20110301
-
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110201
-
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Antimicrobial agents and chemotherapy 20110201
-
HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
European journal of medicinal chemistry 20110201
-
Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method.
Journal of mass spectrometry : JMS 20110201
-
Initial results reported on raltegravir once-daily dosing.
AIDS patient care and STDs 20110201
-
Indications for the use of next-generation antiretroviral drugs in current clinical practice.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101
-
Long-term safety from the raltegravir clinical development program.
Current HIV research 20110101
-
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Clinical drug investigation 20110101
-
Use of maraviroc-, raltegravir-, and etravirine-containing regimens in treatment-experienced patients: a case-series study.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101
-
Interaction between antiretroviral drugs and acenocoumarol.
Antiviral therapy 20110101
-
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
Antiviral therapy 20110101
-
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
PloS one 20110101
-
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
HIV clinical trials 20110101
-
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 20110101
-
Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
Antiviral therapy 20110101
-
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Antiviral therapy 20110101
-
Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.
Drug metabolism and drug interactions 20110101
-
Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
HIV clinical trials 20110101
-
Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572).
Bioscience trends 20110101
-
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Antiviral therapy 20110101
-
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
HIV clinical trials 20110101
-
Effect of raltegravir on the pharmacokinetics of methadone.
Journal of clinical pharmacology 20101201
-
The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors.
Clinical immunology (Orlando, Fla.) 20101201
-
Integrase inhibitors in the treatment of HIV-1 infection.
The Journal of antimicrobial chemotherapy 20101201
-
Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
Antiviral research 20101201
-
Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Therapeutic drug monitoring 20101201
-
HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
AIDS research and human retroviruses 20101201
-
Emergence of raltegravir-resistant HIV-1 in the central nervous system.
International journal of STD & AIDS 20101201
-
Raltegravir-induced cerebellar ataxia.
AIDS (London, England) 20101113
-
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
Journal of molecular and cellular cardiology 20101101
-
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
International journal of STD & AIDS 20101101
-
First-line raltegravir. No evidence of comparative effectiveness.
Prescrire international 20101101
-
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
AIDS (London, England) 20101023
-
Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Journal of acquired immune deficiency syndromes (1999) 20101001
-
Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: selection of the scaffold.
Bioorganic & medicinal chemistry letters 20101001
-
Characterization of integrase region polymorphisms in HIV type 1 CRF06_cpx viruses in treatment-naive patients in Estonia.
AIDS research and human retroviruses 20101001
-
Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.
Biochemistry 20100928
-
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
AIDS (London, England) 20100924
-
High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.
AIDS (London, England) 20100924
-
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
AIDS (London, England) 20100910
-
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999) 20100901
-
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Journal of acquired immune deficiency syndromes (1999) 20100901
-
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Journal of virology 20100901
-
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
The Journal of antimicrobial chemotherapy 20100901
-
Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
Current HIV research 20100901
-
Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.
Bioorganic & medicinal chemistry letters 20100901
-
Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Expert opinion on drug metabolism & toxicology 20100901
-
Novel integrase inhibitors for HIV.
Expert opinion on investigational drugs 20100901
-
[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
Medecine et maladies infectieuses 20100901
-
Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
The Journal of pharmacology and experimental therapeutics 20100801
-
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
PLoS medicine 20100801
-
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
AIDS (London, England) 20100717
-
Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.
AIDS (London, England) 20100717
-
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Virology 20100705
-
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Scandinavian journal of infectious diseases 20100701
-
Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution.
The Journal of infection 20100701
-
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
The Journal of antimicrobial chemotherapy 20100601
-
Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir.
Archives of dermatology 20100601
-
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
Biochemistry 20100504
-
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.
The Journal of antimicrobial chemotherapy 20100501
-
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Antiviral research 20100501
-
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
The Annals of pharmacotherapy 20100501
-
[Integrase inhibitor: raltegravir also as first line therapy].
MMW Fortschritte der Medizin 20100429
-
[Raltegravir: initially as effective as standard therapy].
MMW Fortschritte der Medizin 20100429
-
Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
Journal of acquired immune deficiency syndromes (1999) 20100401
-
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Journal of acquired immune deficiency syndromes (1999) 20100401
-
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Nature medicine 20100401
-
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
Journal of acquired immune deficiency syndromes (1999) 20100401
-
A single-center cohort experience of raltegravir in salvage patients failing therapy.
Journal of acquired immune deficiency syndromes (1999) 20100401
-
Natural polymorphisms of integrase among HIV type 1-infected South African patients.
AIDS research and human retroviruses 20100401
-
Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients.
AIDS (London, England) 20100327
-
A dynamic model of HIV integrase inhibition and drug resistance.
Journal of molecular biology 20100326
-
Raltegravir: in treatment-naive patients with HIV-1 infection.
Drugs 20100326
-
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315
-
Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.
British journal of haematology 20100301
-
Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
The Journal of antimicrobial chemotherapy 20100301
-
Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
The Journal of antimicrobial chemotherapy 20100301
-
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
The Journal of antimicrobial chemotherapy 20100301
-
Raltegravir: is a 400 mg once-daily dose enough?
The Journal of antimicrobial chemotherapy 20100301
-
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
International journal of STD & AIDS 20100301
-
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.
Scandinavian journal of infectious diseases 20100301
-
[Advance and perspective of antiretroviral therapy].
Nihon rinsho. Japanese journal of clinical medicine 20100301
-
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100215
-
Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201
-
New therapeutic strategies for raltegravir.
The Journal of antimicrobial chemotherapy 20100201
-
Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.
The Annals of pharmacotherapy 20100201
-
[The newest developments in anti-HIV-1 drugs].
Yao xue xue bao = Acta pharmaceutica Sinica 20100201
-
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet (London, England) 20100130
-
A case of rhabdomiolysis associated with raltegravir use.
AIDS (London, England) 20100128
-
LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor.
Journal of pharmaceutical and biomedical analysis 20100105
-
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
AIDS (London, England) 20100102
-
Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
Antiviral research 20100101
-
Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100101
-
Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Journal of medical virology 20100101
-
Integrase inhibitors: a novel class of antiretroviral agents.
The Annals of pharmacotherapy 20100101
-
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
British journal of clinical pharmacology 20100101
-
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
PloS one 20100101
-
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
Retrovirology 20100101
-
Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.
PloS one 20100101
-
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Antiviral therapy 20100101
-
The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.
PloS one 20100101
-
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
European journal of medical research 20100101
-
Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.
Retrovirology 20100101
-
ICAAC update. Three new drugs in development, plus Isentress with Reyataz.
Positively aware : the monthly journal of the Test Positive Aware Network 20100101
-
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
Antiviral therapy 20100101
-
An examination of drug-drug interactions with raltegravir.
HIV clinician 20100101
-
From bench to clinic: accessing promising investigational medications for patients with HIV infection in an urban family health center.
Journal of the American Board of Family Medicine : JABFM 20100101
-
Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.
HIV clinical trials 20100101
-
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Antiviral therapy 20100101
-
Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
Retrovirology 20100101
-
A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial.
HIV clinical trials 20100101
-
Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
HIV clinical trials 20100101
-
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
Antiviral therapy 20100101
-
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
PloS one 20100101
-
[Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Terapevticheskii arkhiv 20100101
-
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20091201
-
Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
Therapeutic drug monitoring 20091201
-
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
Expert opinion on pharmacotherapy 20091201
-
The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.
Expert review of anti-infective therapy 20091201
-
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
AIDS (London, England) 20091113
-
[Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110
-
[Status of anti-HIV drug development and an overview of combined chemotherapy].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110
-
A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.
Journal of virological methods 20091101
-
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 20091101
-
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
The Journal of antimicrobial chemotherapy 20091101
-
Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101
-
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101
-
Maraviroc and raltegravir.
British journal of clinical pharmacology 20091101
-
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
AIDS (London, England) 20091023
-
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091015
-
Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20091001
-
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
The Journal of antimicrobial chemotherapy 20091001
-
The effect of raltegravir on the glucuronidation of lamotrigine.
Journal of clinical pharmacology 20091001
-
Raltegravir: a new choice in HIV and new chances for research.
Lancet (London, England) 20090905
-
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet (London, England) 20090905
-
Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.
ChemMedChem 20090901
-
Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.
AIDS patient care and STDs 20090901
-
FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
AIDS alert 20090901
-
A cascade approach to cyclic aminonitrones: reaction discovery, mechanism, and scope.
Organic letters 20090806
-
Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.
Journal of acquired immune deficiency syndromes (1999) 20090801
-
Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090801
-
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
Bioorganic & medicinal chemistry letters 20090801
-
Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.
AIDS research and human retroviruses 20090801
-
Raltegravir as effective as efavirenz in 144-week data.
AIDS patient care and STDs 20090801
-
FDA notifications. Raltegravir indication extended for treatment-naive patients.
AIDS alert 20090801
-
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.
AIDS (London, England) 20090731
-
Evolution of raltegravir resistance during therapy.
The Journal of antimicrobial chemotherapy 20090701
-
Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.
AIDS research and human retroviruses 20090701
-
Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.
Journal of acquired immune deficiency syndromes (1999) 20090701
-
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Clinical pharmacology and therapeutics 20090601
-
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
The Journal of antimicrobial chemotherapy 20090601
-
Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
Drugs 20090529
-
Treatment of HIV infection with raltegravir.
Expert opinion on pharmacotherapy 20090501
-
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
MMW Fortschritte der Medizin 20090430
-
[New antiretroviral drug classes in HIV therapy].
MMW Fortschritte der Medizin 20090430
-
Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.
AIDS (London, England) 20090427
-
Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.
Drug metabolism and disposition: the biological fate of chemicals 20090401
-
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
The Journal of antimicrobial chemotherapy 20090401
-
Raltegravir: the first HIV type 1 integrase inhibitor.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090401
-
Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV.
IUBMB life 20090401
-
FDA notifications. FDA grants approval for raltegravir.
AIDS alert 20090401
-
CROI 2009: a few key presentations on antiretroviral therapy.
The AIDS reader 20090401
-
Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
The AIDS reader 20090401
-
Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disaster.
Journal watch. AIDS clinical care 20090401
-
A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.
The Journal of antimicrobial chemotherapy 20090301
-
Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
Project Inform perspective 20090301
-
Isentress equal to Sustiva in first line therapy.
Project Inform perspective 20090301
-
Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 20090220
-
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
AIDS (London, England) 20090220
-
Effects of omeprazole on plasma levels of raltegravir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090215
-
Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
Journal of acquired immune deficiency syndromes (1999) 20090201
-
Raltegravir and etravirine are active against HIV type 1 group O.
AIDS research and human retroviruses 20090201
-
[Raltegravir as first integrase inhibitor in an HIV-infection].
Nederlands tijdschrift voor geneeskunde 20090131
-
Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Biochemistry 20090113
-
Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
Annual review of pharmacology and toxicology 20090101
-
Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.
Retrovirology 20090101
-
Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101
-
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
Antiviral therapy 20090101
-
Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101
-
HIV dynamics and integrase inhibitors.
Antiviral chemistry & chemotherapy 20090101
-
Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.
Antiviral therapy 20090101
-
New hexahydrodiazocino-naphthyridine triones as HIV-1 integrase inhibitors: WO2008048538 A1.
Expert opinion on therapeutic patents 20090101
-
HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
Journal of molecular recognition : JMR 20090101
-
Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
TreatmentUpdate 20090101
-
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
PloS one 20090101
-
Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
HIV clinical trials 20090101
-
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Retrovirology 20090101
-
Raltegravir: molecular basis of its mechanism of action.
European journal of medical research 20090101
-
Drug-drug interactions with raltegravir.
European journal of medical research 20090101
-
Raltegravir in treatment naive patients.
European journal of medical research 20090101
-
Raltegravir use in special populations.
European journal of medical research 20090101
-
HIV resistance to raltegravir.
European journal of medical research 20090101
-
Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.
HIV clinical trials 20090101
-
[Desensitization to tipranavir caused by toxicodermia].
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101
-
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
HIV clinical trials 20090101
-
An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
Therapeutic drug monitoring 20081201
-
Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.
AIDS clinical care 20081201
-
Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of action.
AIDS clinical care 20081201
-
Raltegravir for postexposure prophylaxis following occupational exposure to HIV.
AIDS (London, England) 20081130
-
Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.
AIDS (London, England) 20081112
-
An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction.
Analytica chimica acta 20081103
-
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
The Journal of antimicrobial chemotherapy 20081101
-
Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
AIDS patient care and STDs 20081101
-
Raltegravir phase III study data released.
AIDS patient care and STDs 20081101
-
Trial will evaluate a once-daily dose of raltegravir.
AIDS patient care and STDs 20081101
-
Antiretroviral treatment update from the 17th International AIDS Conference.
The AIDS reader 20081101
-
[Raltegravir: the first HIV integrase inhibitor. Introduction].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[Pharmacokinetics and interactions of raltegravir].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[Efficacy of raltegravir: from healthy volunteers to phase III trials].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[Secondary effects associated with raltegravir].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[Resistance to integrase inhibitors].
Enfermedades infecciosas y microbiologia clinica 20081101
-
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Enfermedades infecciosas y microbiologia clinica 20081101
-
Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
HIV medicine 20081001
-
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 20081001
-
Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase inhibitors.
Bioorganic & medicinal chemistry 20081001
-
[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Revista clinica espanola 20081001
-
Raltegravir: the first HIV integrase inhibitor.
Clinical therapeutics 20081001
-
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Enfermedades infecciosas y microbiologia clinica 20081001
-
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
Journal of medicinal chemistry 20080925
-
Exacerbation of depression associated with starting raltegravir: a report of four cases.
AIDS (London, England) 20080912
-
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
AIDS (London, England) 20080912
-
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Biochemistry 20080909
-
Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.
Expert review of anti-infective therapy 20080801
-
Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
Current opinion in investigational drugs (London, England : 2000) 20080801
-
A conventional LC-MS method developed for the determination of plasma raltegravir concentrations.
Biological & pharmaceutical bulletin 20080801
-
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 20080724
-
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 20080724
-
Severe rhabdomyolysis associated with raltegravir use.
AIDS (London, England) 20080711
-
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080701
-
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
The Journal of infection 20080701
-
New drugs08, part 2.
Nursing 20080701
-
Integrase inhibitors for the treatment of HIV infection.
Current opinion in drug discovery & development 20080701
-
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
AIDS (London, England) 20080619
-
Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
Journal of clinical pharmacology 20080601
-
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Journal of HIV therapy 20080601
-
Raltegravir treatment response in an HIV-2 infected patient: a case report.
AIDS (London, England) 20080531
-
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515
-
Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515
-
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.
AIDS patient care and STDs 20080501
-
Raltegravir: an integrase inhibitor for HIV-1.
Expert opinion on investigational drugs 20080301
-
[New drugs for HIV infection].
Revue de l'infirmiere 20080301
-
Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.
AIDS (London, England) 20080219
-
Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.
Bioorganic & medicinal chemistry letters 20080215
-
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Clinical pharmacology and therapeutics 20080201
-
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Journal of clinical pharmacology 20080201
-
[New therapeutic options in protracted HIV-infected patients with virological failure].
Medicina clinica 20080126
-
Two new drugs for HIV infection.
The Medical letter on drugs and therapeutics 20080114
-
Raltegravir.
Drugs 20080101
-
Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.
Expert opinion on investigational drugs 20080101
-
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Pharmacotherapy 20080101
-
New drugs: doripenem, raltegravir, and ixabepilone.
Journal of the American Pharmacists Association : JAPhA 20080101
-
The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
Progress in medicinal chemistry 20080101
-
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.
Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101
-
Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.
Journal of addictive diseases 20080101
-
Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.
Positively aware : the monthly journal of the Test Positive Aware Network 20080101
-
Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Antiviral therapy 20080101
-
No residual activity of raltegravir after development of 148 complex mutations in vivo.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101
-
Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Drugs of today (Barcelona, Spain : 1998) 20071201
-
Raltegravir, a new HIV integrase inhibitor.
AIDS clinical care 20071201
-
FDA notifications. Accelerated approval for raltegravir tablets.
AIDS alert 20071201
-
Substituted 2-pyrrolinone inhibitors of HIV-1 integrase.
Bioorganic & medicinal chemistry letters 20071115
-
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
AIDS (London, England) 20071112
-
[Raltegravir an integrase inhibitor--a great leap forward within reach].
Medizinische Monatsschrift fur Pharmazeuten 20071101
-
FDA approves raltegravir tablets.
AIDS patient care and STDs 20071101
-
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Journal of acquired immune deficiency syndromes (1999) 20071001
-
Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070915
-
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
Drug metabolism and disposition: the biological fate of chemicals 20070901
-
Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.
Xenobiotica; the fate of foreign compounds in biological systems 20070901
-
48-week data on raltegravir in naive patients.
AIDS patient care and STDs 20070901
-
Approval recommended for raltegravir in experienced patients.
AIDS patient care and STDs 20070901
-
Pivotal moments in HIV treatment: the 14th CROI.
The AIDS reader 20070501
-
Advances in HIV therapeutics: the 14th CROI.
The AIDS reader 20070501
-
Raltegravir: a new antiretroviral class for salvage therapy.
Lancet (London, England) 20070414
-
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Lancet (London, England) 20070414
-
Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.
JAMA 20070411
-
New drugs offer options.
The AIDS reader 20070401
-
Raltegravir demonstrates potency.
AIDS patient care and STDs 20070401
-
Anti-HIV agents. New drugs, new hope, old lessons.
TreatmentUpdate 20070201
-
Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
TreatmentUpdate 20070201
-
Anti-HIV agents. Raltegravir--other issues.
TreatmentUpdate 20070201
-
Expanded access drug profile: raltegravir (RAL, MK-0518).
The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20070101
-
Anti-HIV agents. New drugs--hope and a degree of caution.
TreatmentUpdate 20070101
-
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 20061215
-
Fuzeon combination highly effective.
AIDS patient care and STDs 20061201
-
Meeting report. Report from ICAAC.
AIDS clinical care 20061201
-
XVI International AIDS Conference: Part 2.
The AIDS reader 20061101
-
AIDS 2006 - XVI International Conference. Time to deliver.
IDrugs : the investigational drugs journal 20061001
-
The latest in antiretroviral therapy.
Drug news & perspectives 20061001
-
The clinical pharmacology of antiretrovirals in development.
Expert opinion on drug metabolism & toxicology 20060601
-
Retrovirus meeting. Novel attacks on HIV move closer to reality.
Science (New York, N.Y.) 20060217
-
MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20060101
-
Integrase inhibitor MK-0518: Merck opens expanded-access program.
AIDS treatment news 20060101
-
Anti-HIV agents. Some drug interactions with Merck's integrase inhibitor.
TreatmentUpdate 20060101
-
Anti-HIV agents. Merck integrase inhibitor.
TreatmentUpdate 20060101